Jun 03, 2026
Johnson & Johnson (JNJ) Stock Rises on Positive Nipocalimab Lupus Trial Data
Johnson & Johnson (JNJ) stock gains as nipocalimab demonstrates sustained lupus control in Phase 2 JASMINE trial, with strong autoantibody-positive results.
The post Johnson & Johnson (JNJ) Stock Rises on Positive Nipocalimab Lupus Trial Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 8 hours ago
SharpLink (SBET) Stock Climbs on Ethlabs Ethereum Research Initiative
- 9 hours ago
Oracle (ORCL) Stock Drops 4.61% as Baystate Health Partnership Expands
- 9 hours ago
Micron (MU) Stock Jumps Over 5% on Strategic Anthropic Partnership
- 10 hours ago
Alphabet (GOOGL) Stock Plunges 6% as AI Talent Exodus Continues to OpenAI and An...
- 11 hours ago
Accenture (ACN) Stock Plummets 25% in Historic Selloff Following Disappointing B...